XOMA Co. (NASDAQ:XOMA) Given Average Recommendation of “Hold” by Analysts

Shares of XOMA Co. (NASDAQ:XOMA – Get Rating) have been assigned a consensus rating of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $49.00.

XOMA has been the subject of a number of recent research reports. Zacks Investment Research downgraded XOMA from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 8th. StockNews.com downgraded XOMA from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. Finally, TheStreet upgraded XOMA from a “c-” rating to a “b-” rating in a research report on Friday, April 1st.

In other XOMA news, CFO Thomas M. Burns sold 2,339 shares of the stock in a transaction on Tuesday, March 22nd. The shares were sold at an average price of $30.02, for a total transaction of $70,216.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James R. Neal sold 1,111 shares of the firm’s stock in a transaction on Wednesday, March 23rd. The stock was sold at an average price of $30.02, for a total transaction of $33,352.22. The disclosure for this sale can be found here. Insiders sold a total of 53,450 shares of company stock valued at $1,553,569 in the last 90 days. 9.89% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XOMA. Geneos Wealth Management Inc. purchased a new stake in XOMA in the 3rd quarter worth approximately $25,000. Citigroup Inc. raised its holdings in shares of XOMA by 118.0% during the fourth quarter. Citigroup Inc. now owns 1,528 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 827 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in XOMA by 138.5% in the third quarter. BNP Paribas Arbitrage SA now owns 1,436 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 834 shares during the period. Barclays PLC lifted its stake in XOMA by 222.0% in the third quarter. Barclays PLC now owns 2,463 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 1,698 shares during the period. Finally, Morgan Stanley boosted its holdings in XOMA by 181.6% in the second quarter. Morgan Stanley now owns 2,630 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 1,696 shares in the last quarter. 56.14% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ XOMA opened at $19.23 on Friday. XOMA has a 12 month low of $18.82 and a 12 month high of $39.49. The firm has a market capitalization of $219.15 million, a price-to-earnings ratio of 128.21 and a beta of 0.89. The business has a 50-day moving average of $24.92 and a 200-day moving average of $23.28.

XOMA (NASDAQ:XOMA – Get Rating) last issued its quarterly earnings data on Tuesday, March 8th. The biotechnology company reported $1.67 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.27 by ($0.60). XOMA had a return on equity of 4.93% and a net margin of 14.57%. The business had revenue of $35.94 million for the quarter, compared to analysts’ expectations of $34.84 million.

About XOMA (Get Rating)

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.

Read More